QualityStocks would like to highlight InVivo Therapeutics Holdings Corp. (OTCBB: NVIV). The company is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital.
In the company’s news yesterday,
InVivo Therapeutics announced former Stryker biomaterials product development specialist Brian Hess as its director of product development.
In the role of director, Hess is responsible for the management, development, and maintenance of InVivo’s pipeline and portfolio of products. Hess will head the effort to transition InVivo technologies from research and development through clinical trials and into production manufacturing by developing specifications, protocols, and reports.
Hess’ most previous role was his eight-year tenure with Stryker, where he developed biomaterial technologies for the orthopedic market. He has led multiple product development teams through the FDA process, and was instrumental in developing HydroSetTM, an injectable calcium phosphate based bone substitute, from concept to product launch. HydroSet has become the market-leading bone scaffold, and in recognition of his success, Stryker awarded Hess and his team with “Best Technology” and “Best Team Synergy.”
Hess’ resume also includes the achievement of being named “Co-Innovator of the Year” in 2010 at Stryker for his work on a novel bone adhesive technology. Hess and his team spent the past three years demonstrating the technology’s feasibility and safety, growing his team to more than 25 engineers and scientists.
“We believe Brian’s past successes in the medical device industry will lead the commercialization of the three products we intend to have under review at FDA this year, as well as help to bring our portfolio of products for other neurological conditions successfully to the market in the coming years,” InVivo CEO Frank Reynolds stated in the press release.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
